NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?
NeuroScientific jumps on early Crohn’s stem cell results
NeuroScientific Biopharmaceuticals (ASX: NSB) surged 43% on Tuesday after announcing promising early results from its stem cell program. Three out of four patients…
